Avadel Pharmaceuticals is currently filing (or may well have already filed) their NDA submission for their narcolepsy drug FT218. The interesting thing about FT218 is that it is the first once-nightly drug for narcolepsy, as opposed to the current Standard of Care which is twice nightly. The problem with twice-nightly is that narcoleptic patients have to wake up IN THE MIDDLE OF THE NIGHT to take the second dose. Therefore, if AVDL's drug is approved (which is a very high probability), the stock will either get bought out by JAZZ pharma (AVDL's competition which dominates the current $1.7 billion market ) or disrupt its entire market, because it's simply the more convenient drug.
For reference, I predicted AIMT's Nestle Buyout 1, here's my DD if ur interested: https://www.youtube.com/watch?v=AwveOt131T4&ab_channel=FinancialGAINZ
Here's my DD on AVDL 🙂
Have a Great Day!
Submitted September 28, 2020 at 08:52PM by SPECULATORjew
via reddit https://ift.tt/36bV3hr